Raymond James Downgrades UroGen Pharma Ltd (URGN); Qunar Cayman Islands Ltd (QUNR) Had 3 Bullish Analysts

November 15, 2017 - By Clifton Ray

Among 4 analysts covering UroGen Pharma Ltd. – Ordinary Shares (URGN), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. UroGen Pharma Ltd. – Ordinary Shares has $37 highest and $2500 lowest target. $31.33’s average target is -25.72% below currents $42.18 stock price. UroGen Pharma Ltd. – Ordinary Shares had 8 analyst reports since May 30, 2017 according to SRatingsIntel. Oppenheimer initiated the stock with “Buy” rating in Tuesday, May 30 report. Oppenheimer maintained it with “Buy” rating and $3200 target in Monday, August 14 report. The rating was initiated by Raymond James with “Buy” on Tuesday, May 30. The firm earned “Buy” rating on Tuesday, May 30 by Jefferies. The rating was maintained by Jefferies on Monday, October 9 with “Buy”. The stock of Urogen Pharma Ltd (NASDAQ:URGN) earned “Buy” rating by Cowen & Co on Wednesday, July 19. The rating was maintained by Oppenheimer with “Buy” on Friday, July 14.

Among 10 analysts covering Qunar Cayman Islands Limited (NASDAQ:QUNR), 3 have Buy rating, 2 Sell and 5 Hold. Therefore 30% are positive. Qunar Cayman Islands Limited had 14 analyst reports since August 25, 2015 according to SRatingsIntel. The stock of Qunar Cayman Islands Ltd (NASDAQ:QUNR) earned “Equal-Weight” rating by Morgan Stanley on Monday, June 20. The company was downgraded on Wednesday, May 4 by CLSA. The rating was maintained by Summit Research on Tuesday, August 25 with “Hold”. The stock of Qunar Cayman Islands Ltd (NASDAQ:QUNR) has “Sell” rating given on Tuesday, October 27 by CLSA. The firm has “Buy” rating by Goldman Sachs given on Monday, October 26. Deutsche Bank downgraded the shares of QUNR in report on Friday, March 18 to “Hold” rating. The stock of Qunar Cayman Islands Ltd (NASDAQ:QUNR) has “Hold” rating given on Friday, October 30 by Stifel Nicolaus. The stock of Qunar Cayman Islands Ltd (NASDAQ:QUNR) has “Overweight” rating given on Tuesday, August 25 by Pacific Crest. Stifel Nicolaus upgraded the stock to “Buy” rating in Friday, August 28 report. The stock of Qunar Cayman Islands Ltd (NASDAQ:QUNR) has “Equal-Weight” rating given on Tuesday, April 26 by Morgan Stanley. See Qunar Cayman Islands Ltd (NASDAQ:QUNR) latest ratings:

The stock decreased 2.50% or $1.08 on November 14, reaching $42.18. About shares traded. Urogen Pharma Ltd (URGN) has 0.00% since November 15, 2016 and is . It has underperformed by 16.70% the S&P500.

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel clinical-stage biopharmaceutical company. The company has market cap of $548.74 million. It is engaged in developing therapies designed to care for urological pathologies. It currently has negative earnings. The Company’s lead product candidates include MitoGel and VesiGel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

>